Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Upgraded Software Enhances Confidence in Flow Cytometry for Hematology Labs

By BiotechDaily International staff writers
Posted on 20 May 2013
An innovative software solution, with cutting-edge image analysis technology for use with a specialized 5-color reagent, has been upgraded to further enhance the performance of flow cytometry in hematology laboratories.

Beckman Coulter Inc. (Pasadena, CA, USA) introduces an advanced version of the innovative “CytoDiff CXP” Autogating Software. The software is an integral part of the company’s unique HematoFlow solution1 —combining diagnostic reagent, hematology and flow cytometry hardware, and IT expertise.

The introduction of Version 2 CytoDiff CXP Autogating software is designed to provide added confidence in the use of flow cytometry in the routine hematology lab for the autovalidation of abnormal samples. Easy-to-use, the advanced Version 2 software further improves sub-population classifications. New features include greater precision in the removal of potential interference and metrics that provide a new “confidence level” on population classification. The new software simplifies the review process, making it easier to validate results with greater certainty.

HematoFlow with the CytoDiff five-color antibody cocktail and CXP Autogating Software make it possible to use the precision of flow cytometry to deliver extended white blood cell (WBC) differential results with far greater consistency than manual microscopic assessment. The CytoDiff five-color antibody cocktail uses six monoclonal antibodies to establish the differential. “HematoFlow with CytoDiff CXP Autogating Software offers enhanced performance by delivering flow cytometry expertise alongside cutting edge image analysis technology applied to each of the multiple population classifiers,” explained Dr. Josee Naegelen, hematology marketing manager, Beckman Coulter Diagnostics Global Product Management and Strategy.

“The routine use of flow cytometry for validating abnormal samples can improve workflow and turnaround time as well as providing access to additional diagnostic information for patients,” said Dr. Naegelen. “This has a significant impact on the lab, enabling it to handle increasing workloads with greater confidence.”

Laboratories are already working with Beckman Coulter to increase confidence in the routine use of flow cytometry in the hematology process for validating abnormal samples. Hospitals including University Hospital, Rennes and Bordeaux (France), Erasme University Hospital, Brussels (Belgium), and several private labs are successfully adopting this approach. They are using Beckman Coulter’s FC 500 flow cytometer and the CytoDiff reagent to establish the extended flow WBC differential, detecting and quantifying normal and abnormal population subsets.

[1] CytoDiff is not available in the United States and other geographies.

Related Links:

Beckman Coulter



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.